ADTRAN
16.7.2024 14:01:35 CEST | Business Wire | Press release
Adtran today announced that telMAX is leveraging its scalable, programmable fiber access technology as it extends its high-speed broadband services to many more communities. The Canadian service provider is harnessing Adtran’s Mosaic CP microservices platform integrated with GLDS BroadHub® subscriber management platform to enable rapid, cost-effective expansion of its network. With advanced automation features, the technology streamlines network management and service activation, empowering telMAX to enhance service delivery, troubleshooting and customer care. The new solution is built on Adtran’s compact SDX 6000 Series of Combo PON optical line terminals (OLTs), along with Adtran’s multigigabit XGS-PON optical network terminals, designed for the most bandwidth-intensive subscribers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716856855/en/
Adtran’s fiber access technology is helping telMAX rapidly expand into new areas. (Photo: Business Wire)
“At telMAX, our mission is to be the premier telecommunications provider in Canada, offering the fastest internet services and the best customer care experience. Leveraging Adtran’s technology has been instrumental in this goal. It’s enabled us to deliver exceptional speed and service, helping us earn recognition from PCMag as Canada’s Fastest ISP for the last two years running,” said Stuart Robert, president of telMAX. “Our new fiber access solution empowers us to perform many operations remotely, ensuring swift, trouble-free installations for our subscribers. The capability to quickly deploy and activate equipment optimizes productivity and significantly reduces manual efforts and operational costs. This efficiency enables us to rapidly expand into new areas, creating ‘fiberhoods’ where residents can enjoy exclusive, lightning-fast internet connectivity.”
telMAX is extending its network to reach more communities across the Greater Toronto Area. Today, they serve a growing customer base in the areas of Newmarket, Stouffville, Brooklin and Aurora. Leveraging Adtran’s technology, including the Mosaic CP platform and SDX Series of OLTs integrated with the GLDS BroadHub® subscriber management and service delivery platform, telMAX is well-equipped to meet the demands of these new markets. The integration allows for real-time adjustments to network conditions and rapid responses to customer demands, significantly enhancing operational efficiencies and scalability. It eliminates swivel-chair operations, removing operational barriers that can slow down workflows, complicate fiber rollouts and introduce friction into customer interactions. By enhancing service quality, minimizing downtime and ensuring heightened network reliability, telMAX will be able to provide superior connectivity and support to its expanding customer base.
“This deployment gives telMAX a more agile and customer-focused network, significantly increasing overall satisfaction as they bring ultra-fast full-fiber broadband to more households and businesses in Southern Ontario,” commented John Scherzinger, GM of Americas sales at Adtran. “Our technology is powering telMAX’s rapid growth, enabling them to expand their network while fostering community development. Seamless connectivity, reaching every street and neighborhood, will bridge the connectivity gap and enhance community engagement. Today’s digitally driven world demands intelligent, flexible networks that guarantee superior service quality. By adopting our Mosaic CP and GLDS’s BroadHub®, telMAX is at the forefront of efforts to transform networks to be more responsive to evolving subscriber needs and expectations.”
“Pairing the subscriber-centered functionality of our BroadHub® platform with the control and orchestration capabilities of Adtran’s Mosaic CP enables telMAX to streamline service delivery and elevate the customer experience. BroadHub® is designed to provide comprehensive customer management and billing solutions that manage the complete customer lifecycle. This integration allows telMAX to simplify operations and efficiently deliver superior customer care,” noted Adam Ross Hill, partner alliance manager at GLDS. “Today’s broadband subscribers expect interactions with their service provider to be efficient and accurate. Using our platform, telMAX can automate service delivery and save their technicians and customers valuable time. In addition to boosting subscriber satisfaction, BroadHub® also offers a cost-effective way to enhance operational efficiency, supporting telMAX’s growth and commitment to community empowerment.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716856855/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
